Newsroom press releases

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)

Products Molecular

Download

29/11/17 - 19:30

Resignation of a Strategic Executive of the Company (233.58 KB)

Other

Download

09/11/17 - 14:15

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)

Financial Data

Download

29/09/17 - 15:00

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)

Financial Data

Download

29/09/17 - 14:15

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)

Acquisition / Partnership

Download

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)

Products Molecular

Download

03/08/17 - 14:45

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)

Financial Data

Download

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)

Products Molecular

Download

25/07/17 - 21:00

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)

Acquisition / Partnership

Download

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)

Products Molecular

Download

26/06/17 - 9:45

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)

Financial Data

Download

23/06/17 - 9:30

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)

Acquisition / Partnership

Download

22/06/17 - 19:45

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)

Acquisition / Partnership

Download

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)

Products Immunodiagnostic

Download

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)

Products Immunodiagnostic

Download

08/05/17 - 19:30

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)

Financial Data

Download

27/04/17 - 18:45

DiaSorin - Annual General Meeting 2016 (421.04 KB)

Financial Data

Download

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)

Products Immunodiagnostic

Download

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)

Products Immunodiagnostic

Download

08/03/17 - 15:30

The Board of Directors approves the results for FY'16 (1.13 MB)

Financial Data

Download

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)

Products Molecular

Download

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)

Products Immunodiagnostic

Download

19/12/16 - 10:00

Co-optation of a Director (333.18 KB)

Financial Data

Download

10/11/16 - 1:00

DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)

Financial Data

Download

02/11/16 - 1:00

DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)

Products Molecular

Download

30/08/16 - 2:00

DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)

Acquisition / Partnership

Download

22/08/16 - 2:00

DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)

Products Immunodiagnostic

Download

04/08/16 - 2:00

The Board of Directors approves results for H1'16 (697.16 KB)

Financial Data

Download

28/07/16 - 2:00

DiaSorin starts selling Vitamin D in Japan (724.4 KB)

Products Immunodiagnostic

Download

14/07/16 - 2:00

DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)

Products Molecular

Download

10/06/16 - 2:00

Weekly report treasury shares buy-back (289.83 KB)

Financial Data

Download

10/06/16 - 2:00

Conclusion buy-back plan (367.77 KB)

Financial Data

Download

07/06/16 - 2:00

DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)

Products Immunodiagnostic

Download

03/06/16 - 2:00

Weekly report treasury shares buy-back (290.21 KB)

Financial Data

Download

30/05/16 - 2:00

Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)

Financial Data

Download

27/05/16 - 2:00

Weekly report treasury shares buy-back (289.34 KB)

Financial Data

Download

20/05/16 - 2:00

Weekly report treasury shares buy-back (290.09 KB)

Financial Data

Download

13/05/16 - 2:00

Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)

Acquisition / Partnership

Download

12/05/16 - 2:00

Start up treasury shares buy-back plan (305.9 KB)

Financial Data

Download

09/05/16 - 2:00

The Board of Directors approves the results for Q1'16 (632.78 KB)

Financial Data

Download

28/04/16 - 2:00

Shareholders' Meeting FY 2015 (365.15 KB)

Financial Data

Download

30/03/16 - 2:00

DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)

Acquisition / Partnership

Download

09/03/16 - 1:00

The Board of Directors approves the results for FY'15 (785.08 KB)

Financial Data

Download

Newsroom press releases

Select year

Newsroom press category

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)

Resignation of a Strategic Executive of the Company (233.58 KB)

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)

DiaSorin - Annual General Meeting 2016 (421.04 KB)

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)

The Board of Directors approves the results for FY'16 (1.13 MB)

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)

Co-optation of a Director (333.18 KB)

DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)

DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)

DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)

DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)

The Board of Directors approves results for H1'16 (697.16 KB)

DiaSorin starts selling Vitamin D in Japan (724.4 KB)

DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)

Weekly report treasury shares buy-back (289.83 KB)

Conclusion buy-back plan (367.77 KB)

DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)

Weekly report treasury shares buy-back (290.21 KB)

Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)

Weekly report treasury shares buy-back (289.34 KB)

Weekly report treasury shares buy-back (290.09 KB)

Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)

Start up treasury shares buy-back plan (305.9 KB)

The Board of Directors approves the results for Q1'16 (632.78 KB)

Shareholders' Meeting FY 2015 (365.15 KB)

DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)

The Board of Directors approves the results for FY'15 (785.08 KB)

Price Sensitive